Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells

Annals of the New York Academy of Sciences

Volumn 784, Issue , 1996, Pages 517-520

  De Vincenzo, R ^a   Scambia, G ^a   Benedetti Panici, P ^a   Bonanno, G ^a   Ercoli, A ^a   Fattorossi, A ^a   Pernisco, S ^a   Isola, G ^a   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FULVESTRANT; GLYCOPROTEIN P; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CELL CULTURE; CELL GROWTH; CELL STRAIN MCF 7; CELL VIABILITY; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG RESISTANCE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHENOTYPE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0029885171     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb16273.x     Document Type: Conference Paper

References (18)

1. MOSCOW, J. A., E. SCHNEIDER & K. H. COWAN. 1993. Multidrug resistance. Cancer Chemother. Biol. Response Modif. Annu. 14: 98.
2. ENDICOTT, J. A. & V. LING. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58: 137.
3. BECK, T. W. 1990. Multidrug resistance and its circumvention. Eur. J. Cancer 26: 513.
4. OZOLS, R. F., R. E. CUNNION, R. W. KLECKER et al. 1987. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5: 641.
5. MILLER, R. L., R. M. BUKOWSKI, G. T. BUDD et al. 1988. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J. Clin. Oncol. 6: 880.
6. RADERER, M. & W. SCHEITHAUER. 1993. Clinical trials of agents that reverse multidrug resistance. Cancer 72: 3553.
7. RAMU, A., D. GLAUBIGER & Z. FUKS. 1984. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and triparanol analogues. Cancer Res. 44: 4392.
8. POMMERENKE, E. W., H. OSSWALD, E. H. HAHN & M. VOLM. 1990. Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells. Cancer Lett. 55: 17.
9. BERMAN, E., M. ADAMS, R. DUIGO-OSTERNDORF et al. 1991. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77[4(15)]: 1318.
10. KIRK, J., S, HOULBROOK, N. S. A. STUART et al. 1993. Differential modulation of doxorubicin to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br. J. Cancer 67: 1189.
11. r 170,000 glycoprotein (gp170) binding studies. Cancer Res. 54: 441.
12. DEGREGORIO, M. W., J. M. FORD, C. C. BENZ & V. J. WIEBE. 1989. Toremifene: pharmacological and pharmacokinetic basis of reversing multidrug resistance. J. Clin. Oncol. 7: 1359.
13. HU, X. F., G. NADALIN, M. DE LUISE et al. 1991. Circumvention of doxorubicin resistance in multidrug-resistant human leukemia and lung cancer cells by the pure antiestrogen ICI 164384. Eur. J. Cancer 27: 773.
14. WAKELING, A. E. & J. BOWLER. 1987. Steroidal pure antiestrogens. J. Endocrinol. 112: 7.
15. WAKELING, A. E., M. DUKES & J. BOWLER. 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51(15): 3867.
16. WAKELING, A. E. 1993. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25: 1.
17. SCAMBIA, G., F. O. RANELLETTI, P. BENEDETTI PANICI et al. 1991. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother. Pharmacol. 28: 255.
18. BERENBAUM, K. C. 1981. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 25: 269.